This content is in French.
HBV: Immunity asleep or awakened?
29 juillet 2025
By Ana Espino | Published on July 29, 2025 | 3 min read
#HepatitisB #Immunity #InfectiousDiseases
Chronic hepatitis B (CHB) remains a major public health issue, affecting more than 296 million people worldwide. Despite the implementation of effective vaccination campaigns, the hepatitis B virus (HBV) continues to cause severe liver complications, including cirrhosis and hepatocellular carcinoma.
Current treatment relies on two main approaches: pegylated interferon (PEG-IFN-
#HepatitisB #Immunity #InfectiousDiseases
Chronic hepatitis B (CHB) remains a major public health issue, affecting more than 296 million people worldwide. Despite the implementation of effective vaccination campaigns, the hepatitis B virus (HBV) continues to cause severe liver complications, including cirrhosis and hepatocellular carcinoma.
Current treatment relies on two main approaches: pegylated interferon (PEG-IFN-
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
: Shu, Y., et al. (2025). Anti-HBV treatment partially restores the dysfunction of innate immune cells and unconventional T cells during chronic HBV infection. Frontiers in immunology, 16, 1611976
View the source
